J&J | JNJ - Current Liabilities


J&J reported $55.46B in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Abbott USD 16.15B 1.66B Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
Baxter International USD 3.81B 218M Sep/2026
Bayer EUR 29.4B 2.87B Sep/2026
Becton, Dickinson and Co. USD 9.54B 139M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
Boston Scientific USD 5.98B 446M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
CONMED USD 458.96M 3.56M Sep/2026
Cooper Companies USD 1.87B 61.9M Jun/2026
Dexcom USD 2.25B 105.1M Sep/2026
Edwards Lifesciences USD 1.58B 68.8M Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Globus Medical USD 507.94M 28.59M Sep/2026
Insulet USD 814.4M 70.2M Sep/2026
Integra LifeSciences USD 329M 1.88M Sep/2026
Intuitive Surgical USD 3.23B 652.4M Sep/2026
J&J USD 55.46B 562M Sep/2026
Medtronic USD 11.8B 141M Jun/2026
Merck USD 28.8B 1.07B Sep/2026
Merit Medical Systems USD 265.08M 150K Sep/2026
Novartis USD 32.52B 777M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 29.77B 2.16B Sep/2026
Stryker USD 6.5B 184M Sep/2026
Tandem Diabetes Care USD 256.08M 3.07M Sep/2026
Teva Pharmaceutical Industries USD 15.42B 221M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026
Zimmer Biomet Holdings USD 3.5B 488.9M Sep/2026
Zoetis USD 2.68B 621M Sep/2026